Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENSEMBLE: SCRT + CAPOXIRI vs CAPOX for LARC
NCT05646511Phase 3Recruiting
- Sponsor
- National Cancer Center Hospital East
- Start
- Nov 2022
- Primary completion
- Dec 2029
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in rectal cancer, sponsored by National Cancer Center Hospital East. Started Nov 2022; status: recruiting.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05646511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05646511.